Anti-TIGIT drugs were once hailed as the future of immuno-oncology. But Roche's two recent clinical trial failures for tiragolumab are raising questions about whether Big Pharmas bet on the wrong horse. Also under discussion is the sector's impressive first-quarter revenue growth. Out of nearly two dozen biopharma companies, more than half generated double-digit growth, including eye-popping increases from mRNA stars Moderna and BioNTech. And Fierce journalists finally got together in person after more than two years. They share what it was like to be in a newsroom once again.
To learn more about the topics in this episode:
To TIGIT or not to TIGIT? Roche's latest trial flop casts shadow on Big Pharma's $6B bet
Roche's TIGIT flop prompts GSK, iTeos to reevaluate next steps for rival drug
Strike 2: Roche flunks another phase 3 lung cancer test to leave TIGIT space reeling
Pfizer, Merck and AstraZeneca led Big Pharma's growth in Q1 but they couldn't match mRNA hotshots
Labcorp's combo COVID, flu, RSV test nabs first green light for direct-to-consumer
Pfizer holding on tight to supplies of COVID-19 drug Paxlovid, limiting the prospect of combination research: report
GlaxoSmithKline is no more: Meet the scaled down 'GSK'
Avanos Medical faces Class I recall for feeding tube system linked to 23 deaths since 2015
Lilly's highly anticipated diabetes drug Mounjaro wins FDA blessing
The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.
See omnystudio.com/listener for privacy information.